Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVs from MSCs for Acute Respiratory Failure
NCT06002841Phase 2Unknown
- Sponsor
- Instituto D’Or de Pesquisa e Ensino
- Start
- Feb 2024
- Primary completion
- Jun 2025
- Modality
- Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of mesenchymal stem cell exosomes in acute respiratory distress syndrome (ARDS) (2 arms), sponsored by Instituto D’Or de Pesquisa e Ensino. Primary endpoint: Measure administration of extracellular vesicles at 28 days. Status: unknown.
02
Drugs
mesenchymal stem cell exosomes
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT06002841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06002841.